Oxidative Stress Increases Susceptibility of Mycobacterium tuberculosis to Isoniazid
Tipo de material:
TextoSeries ; Antimicrobial Agents and Chemotherapy, 46(9), p.2765-2771, 2002Trabajos contenidos: - Bulatovic,V.M
- Wengenack, N.L
- Uhl, J.R
- Hall, L
- Roberts, G.D
- Cockerill, F.R
- Rusnak, F
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
Documentos solicitados
|
CICY Documento préstamo interbibliotecario | Ref1 | B-8238 (Browse shelf(Opens below)) | Available |
Browsing CICY shelves, Shelving location: Documento préstamo interbibliotecario, Collection: Ref1 Close shelf browser (Hides shelf browser)
Isoniazid is a first-line antibiotic used in the treatment of infections caused by Mycobacterium tuberculosis. Isoniazid is a prodrug requiring oxidative activation by the catalase-peroxidase hemoprotein, KatG. Resistance to isoniazid can be obtained by point mutations in the katG gene, with one of the most common being a threonine-for-serine substitution at position 315 (S315T). The S315T mutation is found in more than 50
There are no comments on this title.
Log in to your account to post a comment.
